Venetoclax with cytarabine as ongoing treatment for acute myeloid leukaemia after remission
Tests venetoclax with cytarabine in adults with acute myeloid leukaemia who reached remission.
Plain-language title generated from the registry record
Registry title: Maintenance Venetoclax in AML Fit Patients
Key facts
- Where
- Sohag, EgyptSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07244367, who can take part
Where in Egypt
- Sohag UniversitySohag, EgyptTaking people
- Sohag University HospitalSohag, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sohag University
- Trial code
- NCT07244367
- Record updated
- 24 November 2025
- Original description
this study will explore the efficacy of maintenance SC cytarabine + venetoclax therapy as regard disease free survival (DFS) in AML fit patients who achieved CR after highly aggressive chemotherapy as bridge for BMT or if BMT will be delayed or canceled due to any other reason.Read full original descriptionShow less
Maintenance Venetoclax Based Therapy Post Complete Remission in AML Fit Patients
this study will explore the efficacy of maintenance SC cytarabine + venetoclax therapy as regard disease free survival (DFS) in AML fit patients who achieved CR after highly aggressive chemotherapy as bridge for BMT or if BMT will be delayed or canceled due to any other reason.
Inclusion: Age : 18 - 60 years . Patients who are not eligible for immediate bone marrow transplantation. Newly diagnosed AML patients who attained CR after 1st line. Refractory / recurrant AML patients who attained CR after 2nd line .
Exclusion: Patients not on CR . Age : younger than 18 or older than 60 . Patients not eligible for bone marrow transplation.